Posted inMarket
Illumina Director Keith Meister Sells $57.2 Million in Company Stock
Illumina director Keith Meister recently sold $57.2 million worth of company stock, according to recent regulatory filing disclosures.
Posted inMarket
Alector Executive Grace Wong-Sarad Executes Share Sale Valued at Over Twenty-Four Thousand Dollars
Discover recent insider trading activity at Alector as executive Grace Wong-Sarad sells shares valued at $24,665. Learn more about the transaction details.
Posted inMarket
Alector CEO Arnon Rosenthal Executes Stock Sale Worth $193,473
Alector CEO Arnon Rosenthal recently sold company shares valued at $193,473. Learn more about the insider trading transaction and details.
Posted inMarket
Tarsus Pharmaceuticals Stock Reaches Record High of 85.29 USD
Tarsus Pharmaceuticals stock achieves a new milestone, hitting an all-time high of 85.29 USD. Discover the latest market valuation details.
Posted inMarket
H.C. Wainwright Reaffirms Ionis Stock Rating Following Zanvastro Approval
H.C. Wainwright maintains its stock rating for Ionis Pharmaceuticals following the regulatory approval of Zanvastro, highlighting market confidence.
Posted inMarket
H.C. Wainwright Reaffirms Buy Rating for Milestone Pharmaceuticals Following Regulatory Nod in China
H.C. Wainwright maintains its Buy rating for Milestone Pharmaceuticals following a significant regulatory approval in China.
Posted inMarket
Fulgent Genetics COO Xie Jian Executes Stock Sale Valued at Over $41000
Discover the details of Fulgent Genetics President and COO Xie Jian recent stock transaction involving shares valued at $41809.
Posted inMarket
Castle Biosciences COO Sells Shares Worth $138,642 in Recent Transaction
Castle Biosciences COO executes a stock sale worth $138,642. Discover the details behind the latest executive transaction.
Posted inMarket
Vaxcyte Strengthens Leadership Team and Accelerates Clinical Trial Timeline
Vaxcyte appoints two new executive leaders and narrows the anticipated trial timeline for its key pneumococcal conjugate vaccine candidate.
Posted inMarket
Eli Lilly-Backed Scribe Therapeutics Surges 67% Following $128.7 Million Upsized IPO
On Thursday, Scribe Therapeutics surged 67% during its market debut on the Nasdaq after raising $128.7 million in an upsized initial public offering, signaling renewed investor enthusiasm for early-stage genetic…
